We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Blood Test Combines Epigenetics, NGS and Machine Learning for Multi-Cancer Early Detection

By LabMedica International staff writers
Posted on 07 Jun 2022

Image: The OverC multi-cancer detection blood test kit has received CE mark (Photo courtesy of Unsplash)

Image: The OverC multi-cancer detection blood test kit has received CE mark (Photo courtesy of Unsplash)

Early detection and treatment are important components of comprehensive cancer control. Cancer, when identified early, is more likely to respond to effective treatment, resulting in a greater probability of surviving as well as less expensive treatment. Now, a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device that detects DNA methylation markers using cfDNA isolated from human peripheral whole blood enables earlier detection and localization of multiple cancer types. The assay includes a semi-automated workflow including cfDNA extraction and library preparation; a sequencing instrument for massively parallel sequencing (MPS) of the pooled libraries; as well as an analysis software for data analysis.

The OverC multi-cancer detection blood test is based on Burning Rock Biotech Limited’s (Shanghai, China) self-developed multi-cancer early detection technology ELSA-seq. The technology combines epigenetics, NGS, and machine learning to achieve multi-cancer early detection. ELSA-seq has successfully accomplished the efficient capture of trace amounts of circulating tumor DNA methylation signals in blood. ELSA-seq has been published in a number of high-impact academic journals. These results demonstrate that ELSA-seq is a highly sensitive test for detection of the trace amounts of tumor-derived methylation signals in plasma samples from multiple cancer types. Burning Rock has received CE marking for its OverC multi-cancer detection blood test which is intended for earlier detection and localization of multiple cancer types in adults of either sex, aged 40-75 years old.

Related Links:
Burning Rock Biotech Limited

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Quantitative POC Immunoassay Analyzer

EASY READER+

Electrolyte Analyzer

BKE-B

LAIR2 Antibody Pair Set

LAIR2 Antibody Pair [Biotin]

Latest Molecular Diagnostics News

Channels

Clinical Chemistry

view channel

Blood Protein Panel Supports Monitoring of Treated Celiac Disease

Celiac disease is an autoimmune condition in which gluten triggers intestinal inflammation that can damage the gut and impair nutrient absorption. Even with a gluten-free diet, some patients may continue... Read more

Hemoglobin Levels May Help Signal Long-Term Dementia Risk

Dementia is a growing health challenge in aging societies, with limited treatment options and no cure. Identifying long-term risk remains difficult, particularly when specialist scans or emerging biomarkers... Read more

Liquid Biopsy Platform Shows Promise for Early Gynecologic Cancer Detection

Gynecologic cancers can be difficult to detect early, particularly when symptoms overlap with benign conditions. Earlier cancer detection remains a diagnostic need in ovarian cancer, described as one of... Read more

Image: Complement C7 was identified through multi-omics analysis, validated across MASLD cohorts, localized to hepatic stellate cell-rich fibrotic regions, and linked to extracellular matrix remodeling. (Image Credit: Dr. Takefumi Kimura from Shinshu University, Japan)

Multi-Omics Study Identifies Blood Marker for MASLD Progression

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality worldwide. As MASLD progresses, fibrosis and liver-related events, including hepatocellular... Read more

Hematology

view channel

Image Credit: Adobe Stock

New Donor Genetic Marker May Help Predict Stem Cell Transplant Success

Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more

Image Credit: American Society of Hematology

Updated Ferritin Thresholds Improve Detection of Iron Deficiency

Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more

New Automated Hemostasis Systems Become Available Across US Laboratories

Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more

Image: Acute myeloid leukemia is an aggressive blood cancer in which relapse remains a major challenge, making MRD detection critical for risk assessment and treatment planning (Image Credit: Shutterstock)

Variation in AML Residual Disease Testing Prompts Push for Standardization

Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read more

Immunology

view channel

Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier

Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read more

Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop

Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed... Read more

Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis

Neonatal sepsis remains difficult to diagnose because early signs can resemble other newborn conditions. Diagnostic delays may increase the risk of complications, death, long-term adverse outcomes, and... Read more

Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection

Lyme disease can be difficult to diagnose during the earliest stages of infection, when conventional serologic testing may have limited sensitivity. Patients may present during a diagnostic gray zone in... Read more

Microbiology

view channel

Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms

Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read more

Image: A health worker from the Mfou District Hospital collects a blood sample for the study (Photo courtesy of Sandrine Nsango, PhD)

Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection

Malaria remains one of the world’s deadliest infectious diseases and has affected humans throughout recorded history. In regions where malaria is common, human genetics have been shaped by the sickle cell... Read more

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Pathology

view channel

Image: Overview of the multiple-instance learning (MIL) workflow, in which each TMA core image is represented as a bag of patches that are encoded and aggregated to generate a slide-level prediction. (Giner F, Pastor-Naranjo Á, Meseguer P, et al. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27156864)

AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis

Ewing sarcoma is a rare malignant tumor that mainly affects children, adolescents, and young adults. It usually arises in bone but can also develop in soft tissue, where its microscopic appearance may... Read more

Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions

Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more

Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation

Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more

Image: The approach images fresh, unprocessed tissue in under a minute, avoiding the slower, labor-intensive staining required in conventional pathology (Image Credit: Adobe Stock)

New AI Model Maps Where Glioblastoma Could Return After Surgery

Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more

Technology

view channel

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Image: Antibody-coated microscopic beads are introduced into a tiny flow channel containing blood plasma. Laser irradiation enhances their interaction with CEACAM-5, a colorectal cancer biomarker, causing the beads to assemble and generate a detectable signal. (Image Credit: Figure reproduced from Iida et al., Nanoscale Horizons(2026), DOI: 10.1039/d6nh00017g. Licensed under CC BY-NC 4.0.)

Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more

$Image: OGT\'s SureSeq next‑generation sequencing portfolio, designed for use with the Hamilton NGS STAR Line (Photo courtesy of Hamilton Company)$

New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs

Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more

Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel

$Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)$

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more

European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing

Estrogen receptor-positive (ER+), HER2-negative advanced breast cancer may require molecular testing to guide treatment selection, with blood-based assays offering a way to identify tumor mutations that... Read more

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more